Subscribe
Logo small
Search

AOTMiT: The Transparency Council will evaluate e.g. drugs for plasmacytoma, rheumatoid arthritis and renal anemia

MedExpress Team

Medexpress

Published Dec. 14, 2022 09:06

AOTMiT: The Transparency Council will evaluate e.g. drugs for plasmacytoma, rheumatoid arthritis and renal anemia - Header image
Źródło: AOTMiT
On Monday, December 19, the next meeting of the Transparency Council.

The agenda includes:
Preparation of positions on the assessment of the legitimacy of qualifying healthcare services as guaranteed services:
• Percutaneous thermoablation using radiofrequency current (RFA) or microwaves (MWA) under the guidance of computed tomography in the indication of primary malignant tumors of the lung (ICD-10: C34.0, C34.1, C34.2, C34.3, C34. 8, C34.9), secondary malignant tumors of the lung (ICD-10: C78.0);
• Percutaneous radiofrequency (RFA) or microwave (MWA) thermal ablation guided by CT or MRI for secondary malignant bone tumors (ICD-10: C79.5), callous osteoma (ICD-10: D16.1) , D16.2, D16.3, D16.4, D16.5, D16.6, D16.7, D16.8, D16.9), primary malignant bone...

Content locked

To gain access to the complete English section of the Medexpress.pl, kindly reach out to us at [email protected].

If you already have an account, please log in

Szukaj nowych pracowników

Dodaj ogłoszenie już za 4 zł dziennie*.

* 4 zł netto dziennie. Minimalny okres ekspozycji ogłoszenia to 30 dni.

Read also